The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this ...

Short interest in Eisai Co Ltd (OTC:ESALF) increased during the last reporting period, rising from 1.32M to 1.48M. This put -% of the company's publicly available shares short. Short interest for ...

Phenylephrine started to be used in OTC decongestants after manufacturers ... driving up healthcare costs. Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...

Eisai Co (ESALF) Company Description: Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the ...

In July 2023, the U.S. FDA fully approved Leqembi for adults with Alzheimer's disease, and subsequently, the companies launched the product in the U.S. for $26.5K. The drug later rolled out in ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...